Kenvue stock (US49177J1025): General Counsel sells $679K in shares

Kenvue Inc. General Counsel Matthew Orlando executed an open-market sale of 38,491.296 shares of common stock on May 8, 2026, at a weighted average price of $17.6583 per share, according to an SEC Form 4 filing as of May 2026. Individual trade prices ranged from $17.651 to $17.675. Following the transaction, Orlando holds 0 shares in direct ownership. The sale totaled approximately $679,690, as reported by Investing.com on May 2026. Kenvue shares trade on the NYSE under ticker KVUE.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Kenvue: core business model

Kenvue operates as a consumer health company, spun off from Johnson & Johnson in 2023. It focuses on self-care, skin health and beauty, and essential health products, including well-known brands like Tylenol, Neutrogena, and Listerine. The company markets its portfolio in over 100 countries, with a strong presence in North America, which accounts for a significant portion of US investor interest due to its NYSE listing and exposure to the US consumer market.

Main revenue and product drivers for Kenvue

Kenvue generates revenue primarily from over-the-counter medicines, skin health, and beauty products. Key drivers include essential health brands such as Tylenol pain relievers and Band-Aid adhesives, alongside skin care lines like Neutrogena. In the US, these categories benefit from steady demand in retail channels, supporting stable cash flows for NYSE-listed consumer health plays.

Why Kenvue matters for US investors

As a NYSE-listed consumer staples name, Kenvue offers US investors exposure to defensive health products resilient to economic cycles. Its brands hold leading positions in the US market, where consumer spending on self-care remains robust, making it relevant for portfolios seeking stability amid volatility.

Conclusion

The recent sale by Kenvue General Counsel Matthew Orlando highlights ongoing insider activity at the consumer health firm, which maintains a focus on core brands amid market dynamics. Investors track such transactions alongside operational performance in the competitive US health sector. Kenvue's NYSE presence continues to draw attention from retail portfolios.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.